⌘K
t
ECO Animal Health Group plc is hosting an R&D Day today, 13 March 2025, for institutional and private investors and analysts, with presentations starting at 2:00pm GMT in London. The event features CEO David Hallas and CFO Chris Wilks; no new information on current trading will be provided. The Company stated it will provide a trading update for the year ending 31 March 2025 in April 2025.
| Date | 13 Mar 2025 |
| Time | 07:00:11 |
| Category | Miscellaneous |
| ID | 4590A |
13 March 2025
ECO Animal Health Group plc
("ECO" or the "Company")
R&D Day
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it is hosting an R&D Day today for institutional and private investors and analysts, with presentations starting at 2:00pm GMT at Andaz London, 40 Liverpool St, London EC2M 7QN.
The event will be led by David Hallas, CEO, and Chris Wilks, CFO, alongside senior leaders from across the Company and an industry expert. Attendees will have the opportunity to gain valuable insights on how the next generation of assets in ECO's R&D pipeline are driving long-term value creation and future proofing the business through innovations in preventative animal health.
For those who would like to join virtually, please register via the dedicated registration page: https://www.equitydevelopment.co.uk/news-and-events/eah-rd-investor-presentation-13march2025.
No new information will be provided on current trading at the R&D Day. For guidance on FY25 trading, the Company asks investors to review the outlook section of the interim results announced on 28 November 2024 as this remains relevant. The Company will provide a trading update for the year ending 31 March 2025 in April 2025.
Following the event, slides and a recording will be made available for viewing on the Investors section of the Company's website.
-Ends-
For further information please contact:
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com